VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Idiopathic Parkinson's disease ( Hughes AJ et al.  │ Idiopathic Parkinson's disease ( Hughes AJ et al.  │     100 │
│ 2001)                                              │ 2001)                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with motor fluctuations                   │ Patients with motor fluctuations                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic Insomnia disorder criteria according to    │ Chronic Insomnia disorder criteria according to    │     100 │
│ the criteria of DMS- V ( American Psychiatric      │ the criteria of DMS- V ( American Psychiatric      │         │
│ Association, 2013) and insomnia severity index \>  │ Association, 2013) and insomnia severity index >   │         │
│ 15                                                 │ 15                                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able to use independently the device required for  │ Able to use independently the device required for  │     100 │
│ treatment by apomorphine                           │ treatment by apomorphine                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Collection of written informed consent (legal      │ Collection of written informed consent (legal      │     100 │
│ obligation for any project under the public health │ obligation for any project under the public health │         │
│ law , bioethics laws and / or CNIL)                │ law , bioethics laws and / or CNIL)                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Affiliate to social security or beneficiary of     │ Affiliate to social security or beneficiary of     │     100 │
│ such a regime                                      │ such a regime                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Atypical Parkinsonian Syndromes                    │ Atypical Parkinsonian Syndromes                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Parkinson's disease with hallucinations            │ Parkinson's disease with hallucinations            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Parkinson's disease with impulse Control disorder  │ Parkinson's disease with impulse Control disorder  │     100 │
│ (ICD)                                              │ (ICD)                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Parkinson's disease already treated with           │ Parkinson's disease already treated with           │     100 │
│ APOMORPHINE pump or justifying the use of the pump │ APOMORPHINE pump or justifying the use of the pump │         │
│ continuously day and night                         │ continuously day and night                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Another obvious severe disease explaining insomnia │ Another obvious severe disease explaining insomnia │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Exclusion for monitoring difficulties (mutation,   │ Exclusion for monitoring difficulties (mutation,   │     100 │
│ insufficient motivation, priority associated       │ insufficient motivation, priority associated       │         │
│ pathology in care)                                 │ pathology in care)                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient unwilling to accept a pump                 │ Patient unwilling to accept a pump                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient not accepting polysomnography and multiple │ Patient not accepting polysomnography and multiple │     100 │
│ sleep latency test                                 │ sleep latency test                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient with health problems or a skin disease     │ Patient with health problems or a skin disease     │     100 │
│ precluding continuous subcutaneous infusion        │ precluding continuous subcutaneous infusion        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female parturient or nursing                       │ Female parturient or nursing                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ antiemetic neuroleptics                            │ antiemetic neuroleptics                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Tetrabenazine                                      │ Tetrabenazine                                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Excessive alcohol consumption                      │ Excessive alcohol consumption                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypersensitivity to apomorphine or one of the      │ Hypersensitivity to apomorphine or one of the      │     100 │
│ excipients                                         │ excipients                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Respiratory Depression                             │ Respiratory Depression                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic impairment                                 │ Hepatic impairment                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intellectual Disability                            │ Intellectual Disability                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Dementia                                           │ Dementia                                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cardiac dysrhythmia precluding treatment with      │ Cardiac dysrhythmia precluding treatment with      │      98 │
│ domperidone or apomorphine (increased QTc ≥ 440 ms │ domperidone or apomorphine (increased QTc = 440 ms │         │
│ in men, QTc ≥ 450 ms in women)                     │ in men, QTc = 450 ms in women)                     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                               │ CHIA Criteria                                     │   Score │
╞═════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 35 Years               │ Hypersensitivity to apomorphine or one of the     │      36 │
│                                                 │ excipients                                        │         │
├─────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 90 Years               │ Female parturient or nursing                      │      36 │
├─────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Contraindications for apomorphine               │ Able to use independently the device required for │      43 │
│                                                 │ treatment by apomorphine                          │         │
├─────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Treatments forbidden in association with        │ Hypersensitivity to apomorphine or one of the     │      45 │
│ apomorphine such as                             │ excipients                                        │         │
├─────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Parkinson's disease with dementia (Montreal     │ Parkinson's disease with impulse Control disorder │      52 │
│ Cognitive Assessment (MoCA) \<25/30 (NASREDDINE │ (ICD)                                             │         │
│ and al., 2012))                                 │                                                   │         │
╘═════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 91
Average Levenshtein Ratio of individual lines: 90.33333333333333
OverAll Ratio: 90.66666666666666
